title: Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells.
abstract: Molecular targeted cancer therapy mediated by nanoparticles (NPs) is a promising strategy to overcome the lack of specificity of conventional chemotherapeutic agents. In this context, the prostate-specific membrane antigen (PSMA) has demonstrated a powerful potential for the management of prostate cancer (PCa). Cancer chemoprevention by phytochemicals is emerging as a suitable approach for the treatment of early carcinogenic processes. Since (-)-epigallocatechin 3-gallate (EGCG) has shown potent chemopreventive efficacy for PCa, we designed and developed novel targeted NPs in order to selectively deliver EGCG to cancer cells. Herein, to explore the recent concept of "nanochemoprevention", we present a study on EGCG-loaded NPs consisting of biocompatible polymers, functionalized with small molecules targeting PSMA, that exhibited a selective in vitro efficacy against PSMA-expressing PCa cells. This approach could be beneficial for high risk patients and would fulfill a significant therapeutic need, thus opening new perspectives for novel and effective treatment for PCa.
authors.affiliation: Porto Conte Ricerche, Località Tramariglio, 07041 Alghero, Sassari, Italy. sannav@portocontericerche.it
authors.forename: Vanna
authors.initials: V
authors.lastname: Sanna
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Pintus
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Roggio
authors.forename: Stefania
authors.initials: S
authors.lastname: Punzoni
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Posadino
authors.forename: Alessandro
authors.initials: A
authors.lastname: Arca
authors.forename: Salvatore
authors.initials: S
authors.lastname: Marceddu
authors.forename: Pasquale
authors.initials: P
authors.lastname: Bandiera
authors.forename: Sergio
authors.initials: S
authors.lastname: Uzzau
authors.forename: Mario
authors.initials: M
authors.lastname: Sechi
mesh_terms: D016588:Anticarcinogenic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D020134:Catalytic Domain; D002392:Catechin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004151:Dipeptides / Q000138:chemical synthesis* / Q000737:chemistry; D004337:Drug Carriers; D006801:Humans; D007700:Kinetics; D008297:Male; D058990:Molecular Targeted Therapy; D053758:Nanoparticles; D011091:Polyesters / Q000138:chemical synthesis* / Q000737:chemistry; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*
chemical_list: D016588:Anticarcinogenic Agents; D004151:Dipeptides; D004337:Drug Carriers; D011091:Polyesters; C558513:poly(lactic-co-glycolic acid)-block-poly(ethylene glycol)-N-(N-(1,3-dicarboxypropyl)carbamoyl)lysine; D002392:Catechin; C045651:epigallocatechin gallate; D017430:Prostate-Specific Antigen